

SIGNS OF PITUITARY PARS INTERMEDIA DYSFUNCTION (PPID) CHECKLIST

Owner's Name _____ Date _____

Horse's Name _____ Veterinarian _____

Concerns About Your Horse's Health _____

ABOUT YOUR HORSE:

Age

- Less than 10 years of age
- 10–14 years of age
- 15–20 years of age
- More than 20 years of age

Sex

- Stallion
- Mare
- Gelding

Breed

- | | | |
|--|--|--|
| <input type="checkbox"/> American Saddlebred | <input type="checkbox"/> Morgan | <input type="checkbox"/> Tennessee Walking Horse |
| <input type="checkbox"/> Appaloosa | <input type="checkbox"/> Paint | <input type="checkbox"/> Thoroughbred |
| <input type="checkbox"/> Arabian | <input type="checkbox"/> Paso Fino | <input type="checkbox"/> Welsh Pony and Cob |
| <input type="checkbox"/> Miniature | <input type="checkbox"/> Quarter Horse | <input type="checkbox"/> Other _____ |

Has your horse ever been diagnosed with Equine Metabolic Syndrome (EMS)?

- Yes No

HAS YOUR HORSE EXHIBITED ANY OF THESE CLINICAL SIGNS?

- | | |
|---|--|
| <input type="checkbox"/> Change in attitude/lethargy | <input type="checkbox"/> Recurrent infections |
| <input type="checkbox"/> Decreased performance | <input type="checkbox"/> Exercise intolerance |
| <input type="checkbox"/> Regional or generalized hypertrichosis | <input type="checkbox"/> Loss of seasonal hair coat shedding |
| <input type="checkbox"/> Delayed hair coat shedding | <input type="checkbox"/> Topline muscle atrophy |
| <input type="checkbox"/> Loss of topline muscle | <input type="checkbox"/> Rounded abdomen |
| <input type="checkbox"/> Abnormal sweating (increased or decreased) | <input type="checkbox"/> Polyuria/polydipsia |
| <input type="checkbox"/> Infertility | <input type="checkbox"/> Dry eye/recurrent corneal ulcers |
| <input type="checkbox"/> Desmitis/tendonitis | <input type="checkbox"/> Increased mammary gland secretions |
| <input type="checkbox"/> Regional adiposity | <input type="checkbox"/> Tendon and suspensory ligament laxity |
| | <input type="checkbox"/> Laminitis/recurrent sole abscesses |

If you check one of these clinical signs, talk to your veterinarian and ask about Prascend® (pergolide tablets), the most proven treatment available to control the clinical signs associated with PPID in horses.¹

IMPORTANT SAFETY INFORMATION: PRASCEND is for use in horses only. Treatment with PRASCEND may cause loss of appetite. Most cases are mild. Weight loss, lack of energy, and behavioral changes also may be observed. If severe, a temporary dose reduction may be necessary. PRASCEND has not been evaluated in breeding, pregnant or lactating horses, and may interfere with reproductive hormones in these horses. PRASCEND tablets should not be crushed due to the potential for increased human exposure. Refer to the package insert for complete product information.

¹ Prascend® (pergolide tablets) [Freedom of Information Summary]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2011.




Prascend®

(pergolide tablets)
1 mg

Dopamine receptor agonist for oral use in horses only

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Description: PRASCEND Tablets are rectangular light red colored, half-scored tablets containing 1 mg pergolide, as pergolide mesylate. Pergolide mesylate is a synthetic ergot derivative and is a potent dopamine receptor agonist. The chemical name of pergolide mesylate is 8B-[[Methylthio] methyl]-6-propylergoline monomethanesulfonate. The chemical structure is:



Indication: For the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing's Disease) in horses.

Dosage and Administration: Administer orally at a starting dose of 2 mcg/kg once daily. Dosage may be adjusted to effect, not to exceed 4 mcg/kg daily.

It has been reported that pergolide tablets may cause eye irritation, an irritating smell, or headache when PRASCEND Tablets are split or crushed. PRASCEND Tablets should not be crushed due to the potential for increased human exposure and care should be taken to minimize exposure when splitting tablets.

The tablets are scored and the calculated dosage should be provided to the nearest one-half tablet increment (see Table 1).

Table 1 Dosing Table

Body Weight	Dosage	
	2 mcg/kg	4 mcg/kg
136 - 340 kg (300 - 749 lb)	0.5 tablet	1 tablet
341 - 567 kg (750 - 1,249 lb)	1 tablet	2 tablets
568 - 795 kg (1,250 - 1,749 lb)	1.5 tablets	3 tablets
796 - 1,022 kg (1,750 - 2,249 lb)	2 tablets	4 tablets

Dosing should be titrated according to individual response to therapy to achieve the lowest effective dose. Dose titration is based on improvement in clinical signs associated with Pituitary Pars Intermedia Dysfunction (PPID) and/or improvement or normalization of endocrine tests (for example, dexamethasone suppression test or endogenous ACTH test).

In some cases, adverse events were reported after a dose increase (see **Post-Approval Experience**).

If signs of dose intolerance develop, the dose should be decreased by half for 3 to 5 days and then titrated back up in 2 mcg/kg increments every 2 weeks until the desired effect is achieved.

Contraindications: PRASCEND is contraindicated in horses with hypersensitivity to pergolide mesylate or other ergot derivatives.

Warnings: Do not use in horses intended for human consumption.

Keep PRASCEND in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

Dogs have eaten PRASCEND tablets that were placed in food intended for horses or dropped during administration of the tablets to the horses. Adverse reactions may occur if animals other than horses ingest PRASCEND tablets (see **Post-Approval Experience**).

Human Warnings: Not for use in humans. Keep this and all medications out of the reach of children. PRASCEND should not be administered by persons who have had adverse reactions to ergotamine or other ergot derivatives.

Pergolide, like other ergot derivatives, may cause emesis, dizziness, lethargy or low blood pressure.

Pregnant or lactating women should wear gloves when administering this product. It has been reported that pergolide tablets may cause eye irritation, an irritating smell, or headache when PRASCEND Tablets are split or crushed. PRASCEND Tablets should not be crushed due to the potential for increased human exposure and care should be taken to minimize exposure when splitting tablets. Consult a physician in case of accidental ingestion by humans.

In case of accidental ingestion seek medical advice immediately and show the package leaflet or the label to the physician.

Precautions: Treatment with PRASCEND may cause inappetence.

The use of PRASCEND in breeding, pregnant, or lactating horses has not been evaluated. The effects of pergolide mesylate on breeding, pregnant, or lactating horses are not known; however, the pharmacologic action of pergolide mesylate suggests that it may interfere with reproductive functions such as lactation.

PRASCEND is approximately 90% associated with plasma proteins. Use caution if administering PRASCEND with other drugs that affect protein binding. Dopamine antagonists, such as neuroleptics (phenothiazines, domperidone) or metoclopramide, ordinarily should not be administered concurrently with PRASCEND (a dopamine agonist) since these agents may diminish the effectiveness of Prascend.

Adverse Reactions:

Pre-Approval Experience: A total of 122 horses treated with PRASCEND Tablets for six months were included in a field study safety analysis.

Clinical sign	# Cases	Cases (%)
Decreased appetite	40	32.8
Lameness	22	18.0
Diarrhea/Loose stool	12	9.8
Colic	12	9.8
Lethargy	12	9.8
Abnormal Weight Loss	11	9.0
Laminitis*	10	8.2
Heart murmur	10	8.2
Death	8	6.6
Tooth disorder	8	6.6
Skin abscess	7	5.7
Musculoskeletal pain	6	4.9
Behavior change	6	4.9

*Three new cases and 7 pre-existing, recurring cases

Inappetence or decreased appetite occurred at one or more meals in 40 of 122 horses treated with Prascend. At the baseline evaluation 1.6% of owners reported a history of inappetence or decreased appetite as compared to the 32.8% of horses that experienced inappetence or decreased appetite during the study. Most cases of inappetence were transient and occurred during the first month of treatment; however, some horses experienced sporadic inappetence throughout the study. Two horses required a temporary reduction in dose due to inappetence during the first month of the study. Both horses returned to their original dose within 30 days.

Weight loss occurred in more than half of the horses in this study; however, weight loss that was considered abnormal was only reported in 11 horses.

Lethargy was reported in 9.8% of horses during the study, and was not reported in any horses at the baseline evaluation.

Behavioral changes were noted in 6 horses including aggression, kicking, agitation, nervous behavior and increased activity. One horse required a temporary reduction in dose due to energetic behavior during the first month of the study.

Eight horses died or were euthanized during the study due to worsening of pre-existing conditions (laminitis, dental disease, septic tenosynovitis), or colic (strangulating lipomas, large colon volvulus).

One mare was inadvertently enrolled in the study while pregnant and experienced dystocia resulting in the death of the foal.

Post-Approval Experience (2019):

The following adverse events are based on post approval adverse drug experience reporting for PRASCEND. Not all adverse events are reported. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data.

The following adverse events in horses are categorized in order of decreasing reporting frequency by body system and in decreasing order of reporting frequency within each body system:

General: anorexia, lethargy, weight loss

Gastrointestinal: diarrhea, abdominal pain/colic

Dermatological: alopecia, hyperhidrosis, dermatitis

Musculoskeletal: laminitis, muscle stiffness/soreness

Neurological: ataxia, seizure, muscle tremors

Behavioral: aggression (to other horses and humans), hyperactivity (anxiety, agitation), other behavioral changes (stud-like behavior, spooky, unpredictable, confused)

Clinical pathology: anemia, elevated liver enzymes, thrombocytopenia

The above adverse events were reported in some horses at starting dose levels, while in the others following a dose increase.

Death (including euthanasia) has been reported.

Adverse events have been reported in dogs following ingestion of tablets prepared for administration to horses.

To report suspected adverse reactions, to obtain a Safety Data Sheet (SDS), or for technical assistance, contact Boehringer Ingelheim Animal Health USA Inc. at 1-888-637-4251. For additional information about adverse drug experience reporting for animal drugs, contact the FDA at 1-888-FDA-VETS or online at <http://www.fda.gov/reportanimalae>.

Clinical Pharmacology: Pergolide mesylate is a synthetic ergot derivative and is a potent dopamine receptor agonist. As with other dopamine agonists, pergolide inhibits the release of prolactin which suggests that it may interfere with lactation. In horses with PPID, pergolide is believed to exert its therapeutic effect by stimulating dopamine receptors, and has been shown to decrease the plasma levels of adrenocorticotropic hormone (ACTH), melanocyte stimulating hormone (MSH), and other pro-opiomelanocortin peptides.¹

Pharmacokinetic information in the horse is based on a study using single oral doses of 10 mcg/kg in six healthy mares between 3 and 17 years of age.² Pergolide was rapidly absorbed; the mean maximum concentration (C_{max}) was 4.05±2.02 ng/mL with the median time to maximum concentration (T_{max}) being 0.415 hours.

The area under the curve (AUC) was 14.08±7.46 hr·ng/mL. The mean half life (T_{1/2}) was 5.86±3.42 hours; the mean apparent oral clearance (CL/F) was 1204 mL/kg/hr; and the mean apparent volume of distribution (V/F) was 3082±1354 mL/kg.

Effectiveness: An open-label, historical control, field study evaluated the effectiveness of PRASCEND for the control of clinical signs of PPID. A total of 122 horses with PPID were enrolled in the study, 113 of which were included in effectiveness evaluations. The success of each horse was based on results of endocrinology testing (dexamethasone suppression test or endogenous ACTH test) and/or improvement in clinical signs related to PPID (hirsutism, hyperhidrosis, polyuria/polydypsia, abnormal fat distribution, and/or muscle-wasting) on the Day 180 evaluation. Based on endocrine testing and investigators' clinical assessment scores, 86 (76.1%) of the 113 evaluable cases were treatment successes.

Table 3 Proportion of Treatment Successes on Day 180

Percent success	lower bound: one-sided 95% confidence interval
76.1% (86/113)	68.6%

Enrolled horses were diagnosed with PPID based on the presence of hirsutism and an abnormal pre-study endocrine test result. All horses were treated with 2 mcg/kg PRASCEND (to the nearest one-half tablet) orally once daily for the first three months. If the endocrine test result on Day 90 was normal or adequately improved, the horse continued on the same dose through Day 180. If the endocrine test result on Day 90 was abnormal, the dose increased to 4 mcg/kg given once daily through Day 180. Forty-seven (41.6%) of the 113 horses included in the effectiveness database required a dose increase at Day 90.

Improvement was noted in scores for all clinical sign categories and in mean results for endocrine tests.

Table 4 Percent of Animals with Improvement in Clinical Signs Relative to Baseline Scores

Clinical sign	Day 90±7 (%)	Day 180±7 (%)
Hirsutism	32.7%	89.2%
Hyperhidrosis	27.4%	42.3%
Polyuria/polydypsia	31.0%	34.2%
Abnormal fat distribution	21.2%	33.3%
Muscle wasting	36.3%	46.0%

Table 5 Endocrine Test Results (mean values)

Test	# Animals	Baseline	Day 90	Day 180
ACTH (pg/mL)	20	73.53	51.12	45.08
DST** (mcg/dL)	93	3.12	1.39	1.47

** Dexamethasone suppression test: Post dexamethasone cortisol concentration

Animal Safety: In a six month target animal safety study healthy adult horses received PRASCEND administered orally, once daily, at doses of either 0 mcg/kg, 4 mcg/kg, 6 mcg/kg, or 8 mcg/kg (0X, 1X, 1.5X, or 2X the maximum recommended dose). There were eight healthy horses (four males and four females) in each treatment group. Doses were prepared by dissolving tablets in approximately 10 mL of a 50% sugar water solution.

PRASCEND treated groups had lower mean heart rates and higher mean temperatures than the control group. Horses in all treatment groups had minimum heart rates within the normal range and maximum temperatures below 101.5°F. One 1.5X horse experienced a mild episode of spasmodic colic on Day 3 that resolved after treatment with flunixin meglumine.

Mean red blood cell counts and hemoglobin values were lower in PRASCEND treated groups as compared to the control group. Other hematology parameters including hematocrit, white blood cells, absolute neutrophils, and absolute lymphocytes exhibited mild, transient decreases as compared to the control group. The hematology parameters generally decreased over the first 30 to 60 days after treatment initiation and then returned to values similar to pre-treatment levels. No treatment related alterations were identified on histopathology evaluation of bone marrow.

Storage: Store at or below 25°C (77°F).

How Supplied: PRASCEND Tablets are available in 1 mg strength — packaged 10 tablets per blister and 60 or 160 tablets per carton.

NDC 0010-4489-01 — 60 tablets

NDC 0010-4489-02 — 160 tablets

Approved by FDA under NADA #141-331

References:

¹ Orth, D.N., Holscher, M.A., Wilson, M.G., et al. (1982). Equine Cushing's Disease: Plasma Immunoreactive Proopiomelanocortin Peptide and Cortisol Levels Basally and in Response to Diagnostic Tests. *Endocrinology*. 110(4):1430-41.

² Wright A, Gehring R, Coetzee H (2008). Pharmacokinetics of pergolide in normal mares. *American College of Veterinary Internal Medicine Forum*, Abstract #36, San Antonio, TX.

Marketed by:

Boehringer Ingelheim Animal Health USA Inc. Duluth, GA 30096

Origin Czech Republic

PRASCEND is a registered trademark of Boehringer Ingelheim Vetmedica GmbH used under license.

© 2022 Boehringer Ingelheim Animal Health USA Inc. All rights reserved.

448901-03

Revised 05/2021

US-EQU-0056-2021-V2